Optimized Biventricular Pacing Allograft Recipients

Status Terminated

Clinical Trial Summary

This study tests optimization of biventricular pacing (BiVP) in patients with dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM) during cardiac transplantation in patients with advanced cardiac failure. It examines the effects of atrioventricular delay (AVD), interventricular delay (VVD or RLD), and left ventricular pacing site (LVPS) on cardiac output (CO). BiVP results are compared to traditional atrial (AAI) pacing at an identical heart rate.

Clinical Trial Description

This study is designed to increase the benefit of biventricular pacing (BiVP), which is an established therapy for advanced heart failure. The investigators will test 6 left ventricular (LV) pacing sites and 16 timing sequences in the operating room just before cardiac transplant. Pacing will be implemented after patients have been anticoagulated and connected to the heart-lung machine. Pacing by previously implanted pacemakers will be suppressed. The investigators will measure cardiac output (CO) by aortic flow probe (AFP), left ventricular (LV) contractility by a combination of trans-septal pressure gradients, and simultaneous left ventricular pressure (LVP)and transesophageal echocardiography (TEE) during transient reduction of inflow of blood to the heart by vena caval occlusion. The goal is to prove that this optimization will increase the amount of blood pumped by the failing heart by 15% as compared with standard atrial (AAI) pacing. The testing protocol is 12.5 minutes in duration, and the entire protocol should be executable in 20 minutes. Care will not be altered otherwise. Results will improve management of the general population of patients with advanced heart failure while minimally increasing the risk to patients undergoing cardiac transplantation. Benefits of this study should include: improved patient selection for BiVP and a decrease in the presently recognized 30-40% incidence of BiVP nonresponders. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01290822
Study type	Interventional
Source	Columbia University
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	January 2007
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05564689` - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
Recruiting	`NCT04982081` - Treating Congestive HF With hiPSC-CMs Through Endocardial Injection	Phase 1
Not yet recruiting	`NCT04703751` - Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents	N/A
Recruiting	`NCT01157299` - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO	N/A
Completed	`NCT00765518` - Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)	Phase 2
Completed	`NCT02115581` - Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy	Phase 4
Recruiting	`NCT04246450` - Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy	N/A
Recruiting	`NCT05799833` - Low QRS Voltages in Young Healthy Individuals and Athletes
Recruiting	`NCT01914081` - Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside	Phase 3
Recruiting	`NCT03061994` - Metabolomic Study of All-age Cardiomyopathy	N/A
Recruiting	`NCT02915718` - A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy	N/A
Completed	`NCT03893760` - Assessment of Right Ventricular Function in Advanced Heart Failure
Not yet recruiting	`NCT01219452` - Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy	Phase 1/Phase 2
Recruiting	`NCT02175836` - Arrhythmia Prediction Trial	N/A
Active, not recruiting	`NCT00962364` - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting	`NCT05026112` - The Arrhythmogenic Potential of Midwall Septal Fibrosis in Dilated Cardiomyopathy
Recruiting	`NCT05237323` - Micophenolate Mofetil Versus Azathioprine in Myocarditis	Phase 3
Recruiting	`NCT04649034` - Intraventricular Stasis In Cardiovascular Disease
Suspended	`NCT03071653` - Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study	Phase 2
Completed	`NCT02619825` - Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Optimized Biventricular Pacing Allograft Recipients — BiBET

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms